Qing Xu
About Qing Xu
Qing Xu is a Manager-Cell Therapy Process Engineer at Bristol Myers Squibb with over 12 years of experience in cancer biology, drug development, and immunology.
Current Role at Bristol Myers Squibb
Qing Xu is currently serving as the Manager-Cell Therapy Process Engineer at Bristol Myers Squibb, located in Summit, New Jersey, USA. With extensive experience in cancer biology, Qing is responsible for overseeing various aspects of cell therapy process engineering. His role includes the development and improvement of manufacturing processes for CAR-T cell therapy, ensuring they align with industry standards and regulatory guidelines.
Experience at Legend Biotech
Qing Xu worked as a Senior Scientist in Cell Therapy at Legend Biotech from 2019 to 2021 in Piscataway, New Jersey. During this period, he was deeply involved in research and development related to CAR-T and other cell therapy techniques. His responsibilities included process development, analytical development, and ensuring the quality control of cell therapy products.
Tenure at FDA
From 2017 to 2019, Qing Xu served as a Research Fellow at the FDA in Silver Spring, Maryland. In this capacity, he contributed to research that aligns with the FDA's guidance on cellular and gene therapies. His work included cGLP and cGMP manufacturing process development, as well as bioassays and analytical development crucial for regulatory compliance and product release.
Postdoctoral Research at National Cancer Institute
Qing Xu conducted postdoctoral research at the National Cancer Institute (NCI) from 2014 to 2017 in Bethesda, Maryland. His research focused on cancer biology, signaling, and immunology, contributing to the advancement of tumor-infiltrating lymphocyte (TIL) and macrophage R&D. During his postdoctoral fellowship, he was involved in two clinical trials, working with multi-disciplinary teams to evaluate projects and analyze clinical endpoints and surrogate biomarkers.
Academic Background and Early Career
Qing Xu holds a Ph.D. in Pathology and Cell Biology from Nanjing Medical University, which he completed between 2007 and 2013. He began his research career as a Technician at the Chinese Academy of Sciences in Shanghai City, China, from 2006 to 2007. Following his Ph.D., he worked as a Visiting Scholar at Thomas Jefferson University from 2010 to 2014. His work spanned various domains of cancer research, establishing his expertise in cell biology and immunology.